Evidence map›Paper›PMID 41640606›Full record

ArticleWorld journal of gastroenterology2026

Stemness CD24 activation promotes hepatocellular carcinoma progression

Yin Cai, Lu-Yin Liu, Xiao-Xiao Xia, Hao Tang, Min Xu, Wen-Li Sai, Deng-Fu Yao, Min Yao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yin CaiDepartment of Oncology, Xinghua People's Hospital, Xinghua 225700, Jiangsu Province, China.
Lu-Yin LiuDepartment of Immunology, Nantong University, Nantong 226001, Jiangsu Province, China.
Xiao-Xiao XiaDepartment of Infectious Diseases, Haian People's Hospital, Haian 226600, Jiangsu Province, China.
Hao TangDepartment of Immunology, Medical School of Nantong University, Nantong University, Nantong 226001, Jiangsu Province, China.
Min XuResearch Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu Province, China.
Wen-Li SaiResearch Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu Province, China.
Deng-Fu YaoResearch Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu Province, China.
Min YaoDepartment of Immunology, Medical School of Nantong University, Nantong University, Nantong 226001, Jiangsu Province, China. erbei@ntu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCluster of differentiation 24 (CD24) serves as a liver cancer stem cell marker, and its upregulation is related to chronic liver disease malignancy. However, the exact relationship between CD24 expression and hepatocarcinogenesis remains unknown.

aimTo investigate CD24 levels among individuals with chronic liver diseases and confirm the alterations in CD24 and programmed death-ligand 1 (PD-L1) expression in a dynamic model of rat hepatocarcinogenesis.

methodsApproved by the ethics committee, CD24 levels were detected in the serum of 129 patients with hepatocellular carcinoma (HCC), 72 patients with chronic hepatitis (CH), 60 patients with liver cirrhosis (LC) and 111 normal control (NC). Receiver operating characteristic curves and clinicopathological characteristics of CD24 were used to evaluate the diagnostic or prognostic value for HCC, and the CD24

resultsCompared with those in the CH, LC and NC groups, the average CD24 level in the HCC group was significantly greater (

conclusionActivated CD24 promoted HCC formation through programmed death-ligand 1 signaling and could be a valuable biomarker for monitoring chronic liver disease malignancy.

Indexed as

Biomarkers, TumorCarcinoma, HepatocellularCD24 AntigenLiver NeoplasmsNeoplastic Stem CellsTumor EscapeAnimalsB7-H1 AntigenDisease ProgressionFemaleHumansLiverLiver CirrhosisMaleMiddle AgedPrognosisB7-H1 AntigenBiomarkers, TumorCD24 AntigenCD24 protein, humanCD274 protein, humanBiomarkerChronic liver diseaseClusters of differentiation 24HepatocarcinogenesisProgrammed death-ligand 1

Identifiers

PMID41640606
PMCPMC12865375

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.